Point-of-Care Molecular Diagnostics Market by Product & Service, Technology, Sample Type, Application, and End User - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW
• 4.2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• 4.3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• 4.4 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.5 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• 4.6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• 4.7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing prevalence of infectious diseases and cancer
    • 5.2.1.2 Increasing focus on decentralized diagnostics and subsequent rise in R&D funding
    • 5.2.1.3 Growing awareness associated with early disease diagnosis
    • 5.2.1.4 Increasing use of POC diagnostic tests
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursements
    • 5.2.2.2 High capital investments and low cost-benefit ratio
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory guidelines that impact product commercialization
    • 5.2.4.2 Introduction of alternative technologies
• 5.3 PRICING ANALYSIS
  • 5.3.1 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023-2025
  • 5.3.2 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023-2025
  • 5.3.3 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF KEY PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
  • 5.7.2 IMPORT DATA (HS CODE 3822)
  • 5.7.3 EXPORT DATA (HS CODE 3822)
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 BARGAINING POWER OF SUPPLIERS
  • 5.9.3 THREAT OF SUBSTITUTES
  • 5.9.4 BARGAINING POWER OF BUYERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY FRAMEWORK
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 EUROPE
      • 5.10.1.2.1 Germany
      • 5.10.1.2.2 UK
      • 5.10.1.2.3 France
      • 5.10.1.2.4 Italy
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
      • 5.10.1.5.1 Africa
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 RT-PCR
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 INAAT (Isolated Nucleic Acid Amplification Technology)
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: RAPID POINT OF CARE PCR TESTING STREAMLINES EMERGENCY CARE FOR HOSPITAL IN GERMANY
  • 5.16.2 CASE STUDY 2: IMPLEMENTATION OF RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
  • 5.16.3 CASE STUDY 3: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION
• 5.17 IMPACT OF AI/GENERATIVE AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI-USE CASES
  • 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE
  • 5.17.5 FUTURE OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
• 5.18 TRUMP TARIFF IMPACT ON POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Physicians' Offices/Clinics
    • 5.18.5.2 Hospitals
    • 5.18.5.3 Research Institutes

6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 ASSAYS & KITS
  • 6.2.1 RECURRENT PURCHASE TO PROPEL MARKET
• 6.3 INSTRUMENTS & ANALYZERS
  • 6.3.1 INCREASING ADOPTION OF ADVANCED POC TECHNOLOGIES TO DRIVE MARKET
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 UTILIZATION OF SOLUTIONS FOR ENHANCED USER EXPERIENCE TO SUPPORT MARKET GROWTH

7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 RT-PCR
  • 7.2.1 HIGH SENSITIVITY AND SPECIFICITY TO BOOST DEMAND
• 7.3 INAAT
  • 7.3.1 COST-BENEFITS AND RAPID AMPLIFICATION ABILITIES TO PROPEL MARKET
• 7.4 OTHER TECHNOLOGIES

8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE

• 8.1 INTRODUCTION
• 8.2 BLOOD SAMPLES
  • 8.2.1 ABILITY TO SUPPORT RAPID DETECTION FOR SEVERAL DISEASES TO PROPEL MARKET
• 8.3 URINE SAMPLES
  • 8.3.1 NON-INVASIVE NATURE AND DETECTION OF LOW BIOMARKER CONCENTRATION TO BOOST DEMAND
• 8.4 OTHER SAMPLE TYPES

9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 RESPIRATORY DISEASES
  • 9.2.1 RISING INCIDENCE OF INFLUENZA AND RSV TO DRIVE MARKET
• 9.3 SEXUALLY TRANSMITTED DISEASES
  • 9.3.1 RISING PREVALENCE OF HPV AND HIV TO DRIVE MARKET
• 9.4 HOSPITAL-ACQUIRED INFECTIONS
  • 9.4.1 GROWING FOCUS ON TARGETED CLINICAL THERAPY FOR REDUCTION IN HAIS TO FUEL MARKET
• 9.5 CANCER
  • 9.5.1 INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO DRIVE MARKET
• 9.6 HEPATITIS
  • 9.6.1 INCREASING PREVALENCE AMONG HIGH-RISK SUBGROUP POPULATIONS TO PROPEL MARKET
• 9.7 GASTROINTESTINAL DISORDERS
  • 9.7.1 RISING INCIDENCE OF IBS TO SUPPORT MARKET GROWTH
• 9.8 OTHER APPLICATIONS

10 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 CAPABILITY TO PURCHASE ADVANCED DIAGNOSTIC EQUIPMENT AND ABILITY TO SUPPORT HIGH PATIENT FOOTFALL TO PROPEL MARKET
    • 10.2.1.1 Sepsis
      • 10.2.1.1.1 Rising requirement for rapid diagnosis & treatment to fuel uptake
    • 10.2.1.2 Gastroenteritis
      • 10.2.1.2.1 Increasing admissions to critical care units and rising focus on molecular tools for diagnosis to fuel uptake
    • 10.2.1.3 Meningoencephalitis
      • 10.2.1.3.1 Initialization of targeted treatment due to high mortality risk to fuel market
    • 10.2.1.4 Other diseases
• 10.3 PHYSICIANS' OFFICES/CLINICS
  • 10.3.1 RAPID RESULTS AND INDIVIDUALIZED CARE TO FUEL MARKET
• 10.4 RESEARCH INSTITUTES
  • 10.4.1 INCREASING FOCUS ON GENOMICS & PROTEOMICS RESEARCH TO BOOST DEMAND
• 10.5 OTHER END USERS

11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 High healthcare expenditure for advanced molecular diagnostic technologies to drive market
  • 11.2.3 CANADA
    • 11.2.3.1 Favorable government initiatives for early disease diagnosis awareness to fuel market
• 11.3 EUROPE
  • 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 11.3.2 GERMANY
    • 11.3.2.1 Universal healthcare coverage and favorable growth for decentralized care settings to fuel market
  • 11.3.3 UK
    • 11.3.3.1 Rising prevalence of STIs to boost demand
  • 11.3.4 FRANCE
    • 11.3.4.1 High disease burden of infectious diseases and cancer to drive market
  • 11.3.5 ITALY
    • 11.3.5.1 Rising demand for high-precision diagnostic tools to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising incidence of respiratory illnesses and HIV to boost demand
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing incidence of influenza and epidemics to propel market
  • 11.4.3 JAPAN
    • 11.4.3.1 Growing access to advanced & affordable healthcare services to fuel market
  • 11.4.4 INDIA
    • 11.4.4.1 Expanding healthcare access and increasing prevalence of HIV to propel market
  • 11.4.5 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 High incidence of hepatitis to support market uptake
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising cases of TB and HAIs to fuel market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 11.6.2 KINGDOM OF SAUDI ARABIA (KSA)
    • 11.6.2.1 Improvements in healthcare infrastructure to drive market
  • 11.6.3 UNITED ARAB EMIRATES (UAE)
    • 11.6.3.1 Rising technological advancements in molecular diagnostics to fuel market
  • 11.6.4 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
• 12.3 REVENUE SHARE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product & service footprint
    • 12.5.5.4 Technology footprint
    • 12.5.5.5 Application footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of key emerging players/startups (1/2)
    • 12.6.5.3 Competitive benchmarking of key startups/SMEs (2/2)
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
  • 12.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 DANAHER CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product/Service launches & approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 BIOMERIEUX
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product/Service launches & approvals
      • 13.1.2.3.2 Deals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Products/Services launches & approvals
      • 13.1.3.3.2 Deals
      • 13.1.3.3.3 Expansions
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 ABBOTT
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Key strengths
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 QIAGEN N.V.
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches & approvals
      • 13.1.5.3.2 Deals
      • 13.1.5.3.3 Expansions
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 QUIDELORTHO CORPORATION
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product/Service launches & approvals
      • 13.1.6.3.2 Deals
      • 13.1.6.3.3 Expansions
  • 13.1.7 CO-DIAGNOSTICS, INC.
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
      • 13.1.7.3.2 Expansions
  • 13.1.8 BIOCARTIS
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product/Service launches & approvals
      • 13.1.8.3.2 Deals
  • 13.1.9 SD BIOSENSOR, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product/Service launches
      • 13.1.9.3.2 Deals
      • 13.1.9.3.3 Other developments
  • 13.1.10 GENEDRIVE PLC
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
• 13.2 OTHER PLAYERS
  • 13.2.1 BINX HEALTH, INC.
  • 13.2.2 MOLBIO DIAGNOSTICS LIMITED
  • 13.2.3 OPGEN, INC.
  • 13.2.4 GENOMADIX
  • 13.2.5 VISBY MEDICAL, INC.
  • 13.2.6 QUANTUMDX GROUP LTD.
  • 13.2.7 DETECTACHEM
  • 13.2.8 LABSYSTEMS DIAGNOSTICS OY
  • 13.2.9 AKONNI BIOSYSTEMS, INC.
  • 13.2.10 UBIQUITOME LIMITED
  • 13.2.11 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
  • 13.2.12 NUCLEIN, LLC
  • 13.2.13 GENES2ME
  • 13.2.14 AXXIN
  • 13.2.15 HUWEL LIFESCIENCES

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
• TABLE 3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
• TABLE 4 REGIONAL HIV DATA, 2024
• TABLE 5 AVERAGE SELLING PRICING TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023-2025
• TABLE 6 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023-2025
• TABLE 7 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
• TABLE 8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS
• TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
• TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
• TABLE 11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
• TABLE 12 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE
• TABLE 14 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
• TABLE 17 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 20 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
• TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS (%)
• TABLE 22 KEY BUYING CRITERIA FOR POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS
• TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE
• TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 25 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 26 KEY ASSAYS & KITS CURRENTLY AVAILABLE
• TABLE 27 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 28 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 29 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 30 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 31 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 32 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 33 KEY INSTRUMENTS & ANALYZERS CURRENTLY AVAILABLE
• TABLE 34 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 35 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 36 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 37 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 38 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 39 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 40 KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE
• TABLE 41 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 42 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 43 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 44 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 45 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 46 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 47 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 48 KEY RT-PCR-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 49 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2023-2030 (USD MILLION)
• TABLE 50 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 51 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 52 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 53 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 55 KEY INAAT-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 56 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 57 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 58 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 59 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 60 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 61 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 62 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 63 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 64 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 65 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 66 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 67 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 68 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 69 KEY BLOOD SAMPLE TYPE-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 70 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 71 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 72 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 74 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 75 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 76 KEY URINE SAMPLE-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 77 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 78 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 81 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 82 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 83 KEY OTHER SAMPLE TYPE-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 84 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 85 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 86 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 87 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 88 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 89 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 90 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 91 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR RESPIRATORY DISEASES CURRENTLY AVAILABLE
• TABLE 92 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 93 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 94 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 95 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 96 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 97 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 98 NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023-2030 (IN MILLIONS)
• TABLE 99 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR SEXUALLY TRANSMITTED DISEASES CURRENTLY AVAILABLE
• TABLE 100 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 101 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 102 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 103 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 104 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 105 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 106 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 107 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 108 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 109 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 110 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 111 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 112 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2023-2030 (USD MILLION)
• TABLE 113 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 114 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 115 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 116 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 117 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 118 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR HEPATITIS CURRENTLY AVAILABLE
• TABLE 119 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 120 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 121 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 122 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 123 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 124 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 125 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR GASTROINTESTINAL DISORDERS CURRENTLY AVAILABLE
• TABLE 126 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 127 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 128 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 129 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 130 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 131 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 132 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR OTHER APPLICATIONS CURRENTLY AVAILABLE
• TABLE 133 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 134 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 135 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 136 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 137 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 138 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 139 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 140 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 141 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 142 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 143 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 144 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 145 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 146 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 147 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS' OFFICES/CLINICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 148 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS' OFFICES/CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 149 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS' OFFICES/CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 150 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS' OFFICES/CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 151 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS' OFFICES/CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 152 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS' OFFICES/CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 153 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 154 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 155 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 156 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 157 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 158 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 159 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 160 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 161 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 162 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 163 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 164 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 165 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 166 NORTH AMERICA: MACROECONOMIC INDICATORS
• TABLE 167 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 168 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 169 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 170 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 171 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 172 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 173 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 174 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 175 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 176 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 177 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 178 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 179 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 180 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 181 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 182 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 183 EUROPE: MACROECONOMIC INDICATORS
• TABLE 184 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 185 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 186 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 187 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 188 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 189 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 190 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 191 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 192 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 193 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 194 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 195 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 196 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 197 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 198 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 199 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 200 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 201 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 202 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 203 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 204 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 205 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 206 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 207 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 208 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 209 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 210 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 211 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 212 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 213 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 214 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 215 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 216 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 217 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 218 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 219 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 220 ASIA PACIFIC: MACROECONOMIC INDICATORS
• TABLE 221 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 222 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 223 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 224 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 225 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 226 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 227 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 228 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 229 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 230 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 231 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 232 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 233 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 234 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 235 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 236 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 237 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 238 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 239 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 240 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 241 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 242 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 243 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 244 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 245 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 246 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 247 LATIN AMERICA: MACROECONOMIC INDICATORS
• TABLE 248 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 249 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 250 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 251 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 252 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 253 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 254 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 255 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 256 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 257 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 258 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 259 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 260 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 261 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 262 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 263 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 264 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 265 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 266 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 267 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 268 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 269 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
• TABLE 270 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 271 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 272 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 273 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 274 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 275 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 276 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 277 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 278 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 279 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 280 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 281 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 282 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 283 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 284 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 285 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 286 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 287 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 288 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 289 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
• TABLE 290 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 291 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, JANUARY 2021-JULY 2025
• TABLE 292 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION
• TABLE 293 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT
• TABLE 294 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
• TABLE 295 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
• TABLE 296 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT
• TABLE 297 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 298 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS (1/2)
• TABLE 299 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
• TABLE 300 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JULY 2025
• TABLE 301 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DEALS, JANUARY 2021-JULY 2025
• TABLE 302 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-JULY 2025
• TABLE 303 DANAHER CORPORATION: COMPANY OVERVIEW
• TABLE 304 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 305 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JULY 2025
• TABLE 306 DANAHER CORPORATION: DEALS, JANUARY 2021-JULY 2025
• TABLE 307 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-JULY 2025
• TABLE 308 BIOMERIEUX: COMPANY OVERVIEW
• TABLE 309 BIOMERIEUX: PRODUCTS/SERVICES OFFERED
• TABLE 310 BIOMERIEUX: PRODUCT/SERVICE APPROVALS, JANUARY 2021-JULY 2025
• TABLE 311 BIOMERIEUX: DEALS, JANUARY 2021-JULY 2025
• TABLE 312 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
• TABLE 313 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 314 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES LAUNCHES & APPROVALS, JANUARY 2021-JULY 2025
• TABLE 315 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-JULY 2025
• TABLE 316 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021-JULY 2025
• TABLE 317 ABBOTT: COMPANY OVERVIEW
• TABLE 318 ABBOTT PRODUCTS/SERVICES OFFERED
• TABLE 319 ABBOTT: DEALS, JANUARY 2021-JULY 2025
• TABLE 320 QIAGEN N.V.: COMPANY OVERVIEW
• TABLE 321 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
• TABLE 322 QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JULY 2025
• TABLE 323 QIAGEN N.V.: DEALS, JANUARY 2021-JULY 2025
• TABLE 324 QIAGEN N.V.: EXPANSIONS, JANUARY 2021-JULY 2025
• TABLE 325 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
• TABLE 326 QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 327 QUIDELORTHO CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JULY 2025
• TABLE 328 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021-JULY 2025
• TABLE 329 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021-JULY 2025
• TABLE 330 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 331 CO-DIAGNOSTICS, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 332 CO-DIAGNOSTICS, INC.: DEALS, JANUARY 2021-JULY 2025
• TABLE 333 CO-DIAGNOSTICS, INC.: EXPANSIONS, JANUARY 2021-JULY 2025
• TABLE 334 BIOCARTIS: COMPANY OVERVIEW
• TABLE 335 BIOCARTIS: PRODUCTS/SERVICES OFFERED
• TABLE 336 BIOCARTIS: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JULY 2025
• TABLE 337 BIOCARTIS: DEALS, JANUARY 2021-JULY 2025
• TABLE 338 SD BIOSENSOR, INC.: BUSINESS OVERVIEW
• TABLE 339 SD BIOSENSOR, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 340 SD BIOSENSOR, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JULY 2025
• TABLE 341 SD BIOSENSOR, INC.: DEALS, JANUARY 2021-JULY 2025
• TABLE 342 SD BIOSENSOR, INC.: OTHER DEVELOPMENTS, JANUARY 2021-JULY 2025
• TABLE 343 GENEDRIVE PLC: COMPANY OVERVIEW
• TABLE 344 GENEDRIVE PLC: PRODUCTS/SERVICES OFFERED
• TABLE 345 BINX HEALTH, INC.: COMPANY OVERVIEW
• TABLE 346 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW
• TABLE 347 OPGEN, INC.: COMPANY OVERVIEW
• TABLE 348 GENOMADIX: COMPANY OVERVIEW
• TABLE 349 VISBY MEDICAL, INC.: COMPANY OVERVIEW
• TABLE 350 QUANTUMDX GROUP LTD.: COMPANY OVERVIEW
• TABLE 351 DETECTACHEM: COMPANY OVERVIEW
• TABLE 352 LABSYSTEMS DIAGNOSTICS OY: COMPANY OVERVIEW
• TABLE 353 AKONNI BIOSYSTEMS, INC.: COMPANY OVERVIEW
• TABLE 354 UBIQUITOME LIMITED: COMPANY OVERVIEW
• TABLE 355 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.: COMPANY OVERVIEW
• TABLE 356 NUCLEIN, LLC: COMPANY OVERVIEW
• TABLE 357 GENES2ME: COMPANY OVERVIEW
• TABLE 358 AXXIN: COMPANY OVERVIEW
• TABLE 359 HUWEL LIFESCIENCES: COMPANY OVERVIEW

List of Figures

• FIGURE 1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 YEARS CONSIDERED
• FIGURE 3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
• FIGURE 4 PRIMARY SOURCES
• FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
• FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
• FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH
• FIGURE 10 DATA TRIANGULATION METHODOLOGY
• FIGURE 11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
• FIGURE 12 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• FIGURE 13 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• FIGURE 14 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 16 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 17 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
• FIGURE 18 INCREASING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TECHNOLOGIES TO PROPEL MARKET
• FIGURE 19 ASSAYS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 20 RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 21 OTHER SAMPLE TYPES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 22 RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 23 HOSPITALS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 24 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
• FIGURE 25 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 26 PATENT ANALYSIS FOR POINT OF CARE MOLECULAR DIAGNOSTICS (JANUARY 2014-DECEMBER 2024)
• FIGURE 27 VALUE CHAIN ANALYSIS OF POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES
• FIGURE 28 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 29 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 30 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 31 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS
• FIGURE 33 KEY BUYING CRITERIA FOR POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS
• FIGURE 34 NUMBER OF DEALS & FUNDING ACTIVITIES IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
• FIGURE 35 MARKET POTENTIAL OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET
• FIGURE 36 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
• FIGURE 37 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT
• FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, 2022-2024
• FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET (2024)
• FIGURE 40 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 41 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT
• FIGURE 42 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 43 EV/EBITDA OF KEY VENDORS
• FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 45 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS
• FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
• FIGURE 47 BIOMERIEUX: COMPANY SNAPSHOT (2024)
• FIGURE 48 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
• FIGURE 49 ABBOTT: COMPANY SNAPSHOT (2024)
• FIGURE 50 QIAGEN N.V.: COMPANY SNAPSHOT (2024)
• FIGURE 51 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)
• FIGURE 52 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 53 BIOCARTIS: COMPANY SNAPSHOT (2022)
• FIGURE 54 SD BIOSENSOR, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 55 GENEDRIVE PLC: COMPANY SNAPSHOT (2024)